IFNA1 and COVID-19: It should be mentioned, though, that, although this could potentially hamper IFN bioactivity and treatment outcome, as in the case of severe COVID-19 patients, the relevance of autoantibody formation during prophylactic treatment, namely in healthy or in pre-symptomatic subjects, is yet to be determined.